Home Latest Articles
Latest Articles
  • Haixia WU, Xiuxiu HUANG, Xingguang LI, Tong ZHANG, Xingqiang DENG, Jiaqiang ZHAO
    World Clinical Drug. 2024, 45(11): 1175-1181.
    Objective

    To analyze the effect of lacosamide (LCM) in the treatment of benign childhood epilepsy with centro-temporal spikes (BECTS) and its effect on spike-wave index (SWI) during non-rapid eye movement.

    Methods

    A total of 36 outpatients or inpatients diagnosed with BECTS in our hospital who received anti-seizure therapy with LCM were enrolled as the LCM group, and 36 children diagnosed with BECTS in the same period with control drug were selected as the control group. Baseline and clinical data of the children were collected and analyzed. Clinical efficacy, SWI, attack frequency, attack duration, cognitive function [Chinese Wechsler intelligence scale for children-the fourth vision (WISC-Ⅳ)] and adverse reactions were compared after 3, 6 and 9 months of treatment.

    Results

    After 3, 6 and 9 months of treatment, the total effective rate of LCM group was higher than that of control group (P<0.05). SWI in both groups was lower than before (P<0.05), and the LCM group was lower than that of the control group (P<0.05). The frequency and duration of attacks in both groups were lower than before (P<0.05), and the LCM group was lower than the control group (P<0.05). After 6 and 9 months of treatment, the scores of operational IQ, verbal IQ and total IQ of WSC-Ⅳ scale in both groups were higher than before. After 3 months of treatment, the above scores in the LCM group were higher than those before treatment (P<0.05), and the scores in the LCM group were higher than those in the control group at all time points (P<0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (P>0.05).

    Conclusion

    LCM is effective in the short and medium term treatment of BECTS, which can improve non-REM SWI and cognitive function, reduce seizures and have high safety.

  • Shenwen YI, Jing LEI, Wei GU, Liang YE
    World Clinical Drug. 2024, 45(11): 1182-1186.
  • Guojie LI, Yifang DENG, Minyu LIU
    World Clinical Drug. 2024, 45(11): 1187-1191.

    Alveolar type Ⅱ epithelial cells (AT2), as alveolar epithelial stem cells, possess significant proliferative and differentiation potential, plays a crucial role in maintaining lung homeostasis and the repair of lung injury. Studies have shown that idiopathic pulmonary fibrosis would occur when the normal function of AT2 is disrupted and transforms into fibrosis-promoting phenotype. Being located on the mucosal surface, AT2 is inevitably exposed to environmental stress, which can have long-lasting effects and ultimately promote the development of fibrosis. At the same time, genetic mutations may also lead to impaired AT2 function and the occurrence of pulmonary fibrosis. Additionally, aging is also one of the significant factors that increase the pathological changes in AT2. The article discussed the regeneration process of AT2 and the pathways that lead to AT2 aging, apoptosis, and dysfunction.

  • Wanping JIANG, Wei GU
    World Clinical Drug. 2024, 45(11): 1192-1198.

    Ground-level ozone pollution poses an existential threat to the health of the human respiratory system, and the role and mechanism of ozone inhalation in the occurrence and development of airway inflammatory diseases are research hotspots. Inhaled ozone mainly reacts with the components of the airway surface liquid and then degrades, while producing reactive oxygen species, lipid oxidation products and other products, thereby stimulating alveolar macrophages and airway epithelial cells, activating cell signaling pathways related to inflammation and changing in pro-inflammatory lipid mediators. All these changes promote the occurrence and development of airway inflammation. This article reviewed the inflammatory phenotypes and related mechanisms of inflammation during the process of ozone-inhalation injury.

  • Ya'nan ZHANG, Xi CHEN, Yongkang ZHENG, Kan ZE, Ye TANG, Dongmei WANG
    World Clinical Drug. 2024, 45(11): 1199-1204.

    Psoriasis is a chronic inflammatory skin disease characterized by red patches and scales, which is difficult to cure and causes significant harm to the patients’ physical and mental health. As one of the commonly used types of traditional Chinese medicine, herbal paste has important clinical value in the treatment and prevention of recurrence of some chronic diseases. Under the guidance of the theory of "preventive treatment of disease" Professor Gu Naifang has achieved satisfactory therapeutic effects through the use of herbal paste for holistic treatment and comprehensive regulation of psoriasis patients. This article introduced Professor Gu Naifang's clinical experience in using herbal paste to prevent and treat psoriasis, and included a case study, in order to provide insights for the clinical application of herbal paste in the prevention and treatment of psoriasis.

  • Mengyun GU, Zhimin SUN, Zixuan YANG, Lei SHI, Minhui ZHENG, Naping TANG
    World Clinical Drug. 2024, 45(11): 1205-1211.

    Immune checkpoint inhibitor (ICI) has become one of the important methods in the treatment of advanced tumors, and has significant survival advantages. However, ICI is often associated with immune-related adverse events (irAE), among which intestinal adverse events (such as colitis) are more common. The main symptoms include diarrhea, abdominal pain and intestinal bleeding. Although intestinal irAE induced by ICI has similar intestinal immune response and medical history characteristics to inflammatory bowel disease, the course of the disease progresses rapidly, and usually involving antagonism of immune signaling pathway and dysactivation of T cells. ICI adverse events (AE) should be confirmed according to clinical manifestations and related examinations, and then treated according to the severity of symptoms. In recent years, a large number of studies based on high-resolution omics data and artificial intelligence technology, especially intestinal flora and in vitro intestinal organoid models, have provided new methods and tools for predicting and evaluating the efficacy of ICI, exploring the mechanism and treatment strategy of irAE.

  • Gang ZHENG
    World Clinical Drug. 2024, 45(10): 1005-1009.

    Neurohormonal signaling is one of the main mechanisms of cardiovascular aging, which specifically includes the renin-angiotensin-aldosterone system, β-adrenergic signaling, and insulin-like growth factor-1. Neurohormonal signals are not only involved in cardiovascular failure, but also associated with various cardiovascular diseases such as hypertension, atrial fibrillation, and heart failure, and there may be a common mechanism between the two. This article reviewed the role of neurohormone signaling in cardiovascular aging, aiming to provide reference for the diagnosis, treatment, and new drugs for cardiovascular diseases in the future.

  • Gang ZHENG
    World Clinical Drug. 2024, 45(10): 1010-1015.

    Mitochondrial dysfunction and cellular aging can accelerate cardiovascular aging through various pathways, leading to the occurrence and development of age-related cardiovascular diseases. Existing evidence suggests that both have the potential to become effective targets for delaying cardiovascular aging. This article reviewed the mechanisms of mitochondrial dysfunction and cellular aging in cardiovascular aging, in order to provide reference for the diagnosis, management and development of therapeutic drugs for cardiovascular diseases in the future.

  • Gang ZHENG
    World Clinical Drug. 2024, 45(10): 1016-1022.

    Loss of protein homeostasis, genomic instability and inflammation all involve in cardiovascular aging, and which is closely related to the occurrence and development of cardiovascular diseases, such as atherosclerosis, heart failure, cardiomyopathy and other. Therefore, protein homeostasis, genomic stability, and inflammation may be therapeutic targets for age-related cardiovascular diseases. This article reviewed the mechanisms of protein homeostasis loss, genomic instability, and inflammation in cardiovascular aging, in order to provide new directions for the prevention, diagnosis, and development of new drugs for cardiovascular diseases in the future.

  • Rong HE, Juan ZHANG, Changhuai ZHOU, Senshan ZHANG, Xu LU
    World Clinical Drug. 2024, 45(10): 1023-1029.
    Objective

    To investigate the effect of budesonide on pneumonia injury induced by respiratory syncytial virus (RSV) in young mice.

    Methods

    Seventy-two BABL/c young mice were randomly divided into healthy control group, RSV group, low dose group, medium dose group, high dose group and positive control group, with 12 mice in each group. The healthy control group was given 50 μl physiological saline nasal drip, and the other 5 groups were given RSV-long virus for modeling. The healthy control group and RSV group were atomized with the same amount of physiological saline, the low, medium and high dose groups were atomized with 0.2, 0.8 and 1.5 mg/kg budesonide suspension, and the positive control group was atomized with 46 mg/kg ribavirin once a day for 7 days. The pulmonary index, lung wet/dry weight ratio (W/D), lung function and RSV load were compared. Treg/helper T cells (Th17) were detected by flow cytometry. The levels of interleukin (IL)-17, IL-21 and IL-22 were measured by enzyme-linked immunosorbent assay. The nuclear factor (NF)-κB protein was detected by western blotting.

    Results

    Compared with healthy control group, pulmonary index, W/D, RSV load, peak exhalation flow (PEF), resistance inspiratory (RI), resistance exhalation (RE), Th17 proportion, lung tissue and serum IL-17, IL-21, IL-22, NF-κB protein in RSV group increased, dynamic lung compliance (Cdyn), Treg, Treg/Th17 proportion were significantly decreased (P<0.05). Compared with RSV group, pulmonary index, W/D, RSV load, PEF, RI, RE, Th17 proportion, lung tissue and serum IL-17, IL-21, IL-22 and NF-κB protein were decreased in low, medium and high dose groups and positive control group, while Cdyn, Treg and Treg/Th17 proportion were increased (P<0.05).

    Conclusion

    Budesonide can reduce pneumonia injury induced by RSV and improve Treg/Th17 ratio in young mice by regulating NF-κB capacity.

News